New Evidence For Kisqali Secures Funding In England For Second-Line Use
The decision by health technology assessment body NICE on Novartis’s advanced breast cancer drug, Kisqali, contrasts sharply with its recommendation for another CDK4/6 inhibitor – Lilly’s Verzenios.
You may also be interested in...
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.
The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.